Rosen says Capricor investors can join securities class action over Deramiocel disclosures

By Atlas Watchline Staff · Legal · August 3, 2026

Rosen Law Firm says it filed a securities class action on behalf of investors who bought Capricor Therapeutics shares during a stated class period and alleges disclosures tied to Deramiocel and an FDA-related resubmission were misleading.

Rosen Law Firm says it filed a securities class action on behalf of investors who bought Capricor Therapeutics shares during a stated class period and alleges disclosures tied to Deramiocel and an FDA-related resubmission were misleading.

Rosen said in a PR Newswire investor notice that the case involves Capricor Therapeutics, Inc. securities traded on Nasdaq under the ticker CAPR. The notice says the class period runs from Dec. 17, 2025, through July 26, 2026, inclusive, and that investors who bought during that span may be entitled to compensation through a contingency fee arrangement.

The notice says investors who want to serve as lead plaintiff must move the court no later than Sept. 28, 2026.

The alleged misstatements center on Capricor’s Deramiocel program, a cell therapy the notice links to treatment for Duchenne muscular dystrophy. Rosen says Capricor changed a pre-specified statistical analysis plan used to review clinical data for Deramiocel, and that the FDA had not agreed to those changes before Capricor resubmitted the Deramiocel Biologics License Application.

According to the notice, that created a significant risk that the FDA could conclude the clinical results did not provide substantial evidence of effectiveness, and a substantial risk to regulatory approval of Deramiocel.

Rosen also alleges that Capricor’s statements about its business, operations and prospects were materially misleading or lacked a reasonable basis. The notice does not include a court docket number, the complaint filing location or a response from Capricor or the FDA.

The investor notice provides a join link and contact information for Phillip Kim, Esq. It does not say whether the claims have been tested in court.

The notice says investors who bought during the class period may seek to join the case, and any investor seeking lead-plaintiff status must act by the Sept. 28 deadline listed in the filing notice.

Sources

• PR Newswire investor notice

Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.

This is the AMP version of the article. Read the full article on Atlas Watchline.